Loading...
XKRX058820
Market cap166mUSD
Jan 02, Last price  
1,758.00KRW
1D
-0.57%
1Q
-18.80%
Jan 2017
-44.72%
Name

CMG Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:058820 chart
P/E
37.82
P/S
2.60
EPS
46.48
Div Yield, %
0.01%
Shrs. gr., 5y
37.79%
Rev. gr., 5y
80.77%
Revenues
93.91b
+14.25%
2,731,224,0003,214,591,0004,108,269,0004,501,223,0003,904,384,0004,476,412,0004,864,985,00050,741,945,00064,459,891,27069,475,495,57082,197,409,66093,906,675,100
Net income
6.46b
P
278,000,000327,438,000445,374,000475,602,00022,938,000176,253,000176,553,0002,641,002,000214,996,4903,165,485,150-388,139,9106,455,349,070
CFO
3.91b
-20.83%
419,963,000528,780,000682,067,000683,316,000355,160,000468,216,000621,552,000721,632,0002,944,288,6305,628,619,9304,937,550,0203,909,002,000
Dividend
Mar 15, 20220.285 KRW/sh
Earnings
Mar 28, 2025

Profile

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutical CO., Ltd. in April 2013. CMG Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.
URL
http://cmgpharma.co.kr/
IPO date
Aug 31, 2001
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
93,906,675
14.25%
82,197,410
18.31%
Cost of revenue
71,243,338
61,820,043
Unusual Expense (Income)
NOPBT
22,663,337
20,377,367
NOPBT Margin
24.13%
24.79%
Operating Taxes
275,684
(866,958)
Tax Rate
1.22%
NOPAT
22,387,653
21,244,325
Net income
6,455,349
-1,763.15%
(388,140)
-112.26%
Dividends
(29,280)
Dividend yield
0.01%
Proceeds from repurchase of equity
(929,110)
BB yield
1.55%
Debt
Debt current
1,086,156
356,412
Long-term debt
25,570,939
7,069,278
Deferred revenue
Other long-term liabilities
2,303,492
48,379
Net debt
(94,734,853)
(70,787,283)
Cash flow
Cash from operating activities
3,909,002
4,937,550
CAPEX
(12,384,200)
(10,307,542)
Cash from investing activities
(28,220,842)
(10,867,979)
Cash from financing activities
21,095,493
5,628,148
FCF
(15,186,861)
14,288,397
Balance
Cash
68,827,058
77,813,221
Long term investments
52,564,890
399,752
Excess cash
116,696,614
74,103,102
Stockholders' equity
83,665,273
78,445,895
Invested Capital
134,989,775
117,249,675
ROIC
17.75%
18.96%
ROCE
10.36%
10.65%
EV
Common stock shares outstanding
138,892
27,804
Price
2,410.00
12.09%
2,150.00
-43.94%
Market cap
334,730,308
459.94%
59,779,675
-45.27%
EV
239,995,455
(10,999,720)
EBITDA
25,220,904
22,661,689
EV/EBITDA
9.52
Interest
79,543
15,277
Interest/NOPBT
0.35%
0.07%